| Dr Thomas Joseph Desmarais, MD | |
|
1233 N 30th St, Billings, MT 59101-0127 | |
| (406) 657-7000 | |
| Not Available |
| Full Name | Dr Thomas Joseph Desmarais |
|---|---|
| Gender | Male |
| Speciality | Vascular Surgery |
| Experience | 10 Years |
| Location | 1233 N 30th St, Billings, Montana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1972918639 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2086S0129X | Surgery - Vascular Surgery | MED-PHYS-LIC-76907 (Montana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Vincent Healthcare | Billings, MT | Hospital |
| Bozeman Health Deaconess Hospital | Bozeman, MT | Hospital |
| Central Montana Medical Center | Lewistown, MT | Hospital |
| Sheridan Memorial Hospital | Sheridan, WY | Hospital |
| St James Healthcare | Butte, MT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Scl Health Medical Group - Billings Llc | 9638491574 | 219 |
News Archive
Blood levels of altered lysosomal proteins may help detect preclinical Alzheimer's disease, researchers report.
Analysis of cancer death data from 2008-2014 in New York state revealed high cancer mortality rates among U.S.-born blacks and Puerto Ricans and relatively low cancer mortality rates among Hispanic South Americans and Asians.
HealthCare.Gov, the consumer health care insurance website run by the federal government, unveiled a slew of new features this morning. Consumers can find pricing information for 4,400 individual and family health plans offered by more than 225 insurance carriers, Plan information will be updated monthly, said Todd Park, HHS chief technology officer.
Actavis plc and Adamas Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Namzaric, a fixed-dose combination (FDC) of memantine hydrochloride extended-release, a NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of gastric cancer, Roche/Genentech/ Chugai's Herceptin as an add-on to standard chemotherapy earns Decision Resources' proprietary clinical gold standard status in 2013, following its approval for the first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive gastric cancer in 2010.
› Verified 8 days ago
| Entity Name | Scl Health Medical Group - Billings Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508289703 PECOS PAC ID: 9638491574 Enrollment ID: O20141204001495 |
News Archive
Blood levels of altered lysosomal proteins may help detect preclinical Alzheimer's disease, researchers report.
Analysis of cancer death data from 2008-2014 in New York state revealed high cancer mortality rates among U.S.-born blacks and Puerto Ricans and relatively low cancer mortality rates among Hispanic South Americans and Asians.
HealthCare.Gov, the consumer health care insurance website run by the federal government, unveiled a slew of new features this morning. Consumers can find pricing information for 4,400 individual and family health plans offered by more than 225 insurance carriers, Plan information will be updated monthly, said Todd Park, HHS chief technology officer.
Actavis plc and Adamas Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Namzaric, a fixed-dose combination (FDC) of memantine hydrochloride extended-release, a NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of gastric cancer, Roche/Genentech/ Chugai's Herceptin as an add-on to standard chemotherapy earns Decision Resources' proprietary clinical gold standard status in 2013, following its approval for the first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive gastric cancer in 2010.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Thomas Joseph Desmarais, MD 2900 12th Ave N Ste 400e, Billings, MT 59101-7514 Ph: (406) 238-6820 | Dr Thomas Joseph Desmarais, MD 1233 N 30th St, Billings, MT 59101-0127 Ph: (406) 657-7000 |
News Archive
Blood levels of altered lysosomal proteins may help detect preclinical Alzheimer's disease, researchers report.
Analysis of cancer death data from 2008-2014 in New York state revealed high cancer mortality rates among U.S.-born blacks and Puerto Ricans and relatively low cancer mortality rates among Hispanic South Americans and Asians.
HealthCare.Gov, the consumer health care insurance website run by the federal government, unveiled a slew of new features this morning. Consumers can find pricing information for 4,400 individual and family health plans offered by more than 225 insurance carriers, Plan information will be updated monthly, said Todd Park, HHS chief technology officer.
Actavis plc and Adamas Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Namzaric, a fixed-dose combination (FDC) of memantine hydrochloride extended-release, a NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of gastric cancer, Roche/Genentech/ Chugai's Herceptin as an add-on to standard chemotherapy earns Decision Resources' proprietary clinical gold standard status in 2013, following its approval for the first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive gastric cancer in 2010.
› Verified 8 days ago
Thomas Mitchell Gallagher, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 2510 17th St W, Billings, MT 59102 Phone: 406-245-3238 Fax: 406-248-6814 | |
Fred V Schneider, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 2900 12th Ave N, Ste 502e, Billings, MT 59101 Phone: 406-245-6982 Fax: 406-245-1539 | |
Robert J Hancock, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 801 N 29th St, Billings, MT 59101 Phone: 406-238-2500 | |
Nolan Mann, M.D. Surgery Medicare: Medicare Enrolled Practice Location: 2800 10th Ave N, Billings, MT 59101 Phone: 406-238-2500 | |
Scott H. Dull, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 801 N 29th St, Billings, MT 59101 Phone: 406-238-2500 | |
Jeffrey R Balison, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 2345 King Ave W, Billings, MT 59102 Phone: 406-651-5670 | |
Bret Murray, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 801 N 29th St, Billings, MT 59101 Phone: 406-238-2500 |